Human IL-5R Antibody - Benralizumab Biosimilar

Human IgG1 afucosylated - CAS #1044511-01-4

ABOUT

Anti-human IL-5R - Benralizumab biosimilar - CAS #1044511-01-4

Anti-hIL-5R-hIgG1fut is a biosimilar antibody of Benralizumab, a human interleukin-5 receptor (IL-5R) antibody that blocks IL-5 signaling. This monoclonal antibody (mAb) specifically targets the alpha subunit of the IL-5R. Benralizumab, also known as MEDI-563, is FDA-approved for the treatment of severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA).

More details More details


Anti-hIL-5R-hIgG1fut comprises the variable region of Benralizumab and the afucosylated IgG1 constant region of Benralizumab for high effector functions. 

This mAb can be used together with HEK-Blue™ IL-5 cells for screening and neutralization assays to block IL-5 signaling induced by recombinant human IL-5 (see figure).

 

Key features

  • Each lot is functionally tested and validated.
  • The complete sequence of the antibody construct was verified.
  • The absence of endotoxins is determined by the EndotoxDetect™ assay.

 

All InvivoGen products are for internal research use only, and not for human or veterinary use.

All products are for research use only, and not for human or veterinary use.

Binding of Anti-hIL-5R Benralizumab
Binding of Anti-hIL-5R Benralizumab

SPECIFICATIONS

Specifications

Target

IL-5R

Target species

Human

Applications

Neutralization assay (tested)

ELISA

Species
Human
Isotype
hIgG1fut
kappa
Recommended isotype control
Human IgG1fut Isotype Control Antibody
Clone
Benralizumab
CAS number
1044511-01-4
Synonyms
MEDI-563
Tag
Tag-free
Source
CHO
Production details
Animal-free
Purification
Protein A
Formulation buffer

Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Preservative
Azide-free
Purity
≥95% (SDS-PAGE)
Appearance (form)
Lyophilized
Reconstitution buffer
Sterile water (not provided)
Endotoxin

Negative (tested using EndotoxDetect™ assay)

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hIL-5R-hIgG1fut
  • Cat code: 
    hil5r-mab13
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Benralizumab is a humanized, afucosylated IgG1 monoclonal antibody (mAb) designed to target the alpha chain of the human interleukin 5 receptor (IL-5Rα), expressed on eosinophils and basophils1. IL-5 plays a critical role in the survival, proliferation, and activation of eosinophils, which contribute to airway inflammation and exacerbations in eosinophilic asthma2. In addition to inhibiting interleukin-5 signaling, Benralizumab leads to eosinophil apoptosis through ADCC1. Benralizumab is FDA-approved for the treatment of severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA)3. 

 

 

 

1. Wechsler ME, et al., 2024. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 390(10):911-921. 
2. Kolbeck R, et al., 2010. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 125(6):1344-1353.e2. 
3. Fasenra (benralizumab) US prescribing information; 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761070s021lbl.pdf

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?